CIK 0001636282 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 0 | 2.3 M | ||
| Net income (USD) | -80.9 M | |||
| Diluted EPS (USD/shares) | -24.86 | -1.52 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-09 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-10-07 | 8-K | 8-K items 1.01,9.01 | 2026-10-05 |
| 2026-10-06 | 424B5 | 424B5 | |
| 2026-10-05 | 424B5 | 424B5 | |
| 2026-10-02 | 4 | FORM 4 | 2026-10-01 |
| 2026-10-02 | 4 | FORM 4 | 2026-10-01 |
| 2026-10-02 | 4 | FORM 4 | 2026-09-30 |
| 2026-10-01 | 144 | 144 | |
| 2026-10-01 | 144 | 144 | |
| 2026-10-01 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-30 | 144 | 144 | |
| 2026-09-08 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-08 |
| 2026-09-03 | 4 | FORM 4 | 2026-09-01 |
| 2026-09-03 | 4 | FORM 4 | 2026-09-01 |
| 2026-09-03 | 4 | FORM 4 | 2026-09-01 |
| 2026-09-01 | 144 | 144 | |
| 2026-08-25 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-08-25 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-10 | 4 | FORM 4 | 2026-08-07 |
| 2026-08-07 | 144 | 144 | |
| 2026-08-07 | 144 | 144 | |
| 2026-08-05 | 4 | FORM 4 | 2026-08-03 |
| 2026-08-05 | 4 | FORM 4 | 2026-08-03 |
| 2026-08-04 | 8-K | 8-K items 2.02,9.01 | 2026-08-04 |
Forms on file (last 1,000): 4 223, 8-K 170, SC 13G/A 66, 3 42, SC 13G 37, 10-Q 32, CORRESP 29, 424B5 23. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=SYRE (0.002 USD), /gw/filings/filings?ticker=SYRE&form=8-K, /gw/filings/facts?ticker=SYRE&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange